# A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy

> **NCT02644486** · NA · TERMINATED · sponsor: **Zhi-Hong Liu, M.D.** · enrollment: 4 (actual)

## Conditions studied

- Obesity and Glomerulopathy

## Interventions

- **DRUG:** High dosage Sevelamer Carbonate + Irbesartan
- **DRUG:** Low dosage Sevelamer Carbonate + Irbesartan
- **DRUG:** Irbesartan

## Key facts

- **NCT ID:** NCT02644486
- **Lead sponsor:** Zhi-Hong Liu, M.D.
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2018-02
- **Final completion:** 2018-02
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** difficulty in enrollment
- **Last updated:** 2018-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02644486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02644486, "A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02644486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*